This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Ionis (IONS) Q4 Earnings Top Estimates, Sales Lag, Stock Down
by Zacks Equity Research
Ionis (IONS) Q4 loss is narrower than expected. However, sales miss estimates. Revenue guidance for 2023 looks soft. Stock down.
How Are Biotech ETFs Reacting to Q4 Earnings Releases?
by Sanghamitra Saha
The latest earnings from some of the big biotech players came in at mixed this reporting season.
Biotech Stock Roundup: BIIB's Q4 Results, EBS and BPMC Offer Updates
by Zacks Equity Research
Earnings results from Biogen (BIIB) and updates from EBS are the key highlights from the biotech sector during the past week.
Compared to Estimates, Biogen Inc. (BIIB) Q4 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Biogen Inc. (BIIB) give a sense of how its business performed in the quarter ended December 2022, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Biogen (BIIB) Beats Q4 Earnings & Sales Estimates, Stock Up
by Zacks Equity Research
Biogen (BIIB) beats fourth-quarter estimates for earnings and sales. Stock rises in pre-market.
Biogen Inc. (BIIB) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Biogen Inc. (BIIB) delivered earnings and revenue surprises of 15.38% and 4.13%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Should BNY Mellon US Mid Cap Core Equity ETF (BKMC) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for BKMC
AbbVie (ABBV) Beats Q4 Earnings Estimates, Misses on Sales
by Zacks Equity Research
AbbVie's Q4 earnings (ABBV) beat estimates, while sales miss the same. Full-year 2023 EPS falls short of estimates.
Biogen Inc. (BIIB) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Biogen Inc. (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Biogen (BIIB) Beat Estimates This Earnings Season?
by Zacks Equity Research
Biogen's (BIIB) sales in the fourth quarter are likely to have been hurt by lower sales of Tecfidera and Spinraza.
Sage and Biogen's NDA for Depression Drug Gets Priority Review
by Zacks Equity Research
Sage Therapeutics, Inc. (SAGE) and partner, Biogen Inc.'s (BIIB) NDA for zuranolone to treat adults with MDD and PPD accepted by the FDA and granted priority review.
Biogen Inc. (BIIB) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Biogen Inc. (BIIB) closed at $288.28 in the latest trading session, marking a +1.64% move from the prior day.
Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Biogen Inc. (BIIB) closed at $285.94 in the latest trading session, marking a -1.43% move from the prior day.
Biogen (BIIB) & Eisai's Lecanemab Secures EMA's MAA Acceptance
by Zacks Equity Research
Biogen (BIIB) and Eisai jointly announce that EMA accepts lecanemab's marketing authorization application (MAA) for the treatment of patients with early-stage Alzheimer's disease, for review.
Eli Lilly (LLY) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Higher demand for its key drugs is likely to have offset generic competition for several other drugs and may have boosted Lilly's (LLY) fourth-quarter sales.
This "Golden" Technical Indicator is Triggering Across the Market
by Andrew Rocco
A Golden Cross is a simple, yet effective technical indicator. Andrew Rocco explains how to use it and relates it back to the current market.
Biogen Inc. (BIIB) Stock Moves -0.02%: What You Should Know
by Zacks Equity Research
In the latest trading session, Biogen Inc. (BIIB) closed at $291.88, marking a -0.02% move from the previous day.
Why Biogen Inc. (BIIB) Could Beat Earnings Estimates Again
by Zacks Equity Research
Biogen Inc. (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XBI
FDA Rejects Accelerated Nod to Lilly's (LLY) Alzheimer's Drug
by Zacks Equity Research
The FDA rejects Eli Lilly's (LLY) seeking accelerated approval of a new Alzheimer's drug, donanemab, due to the limited number of patients with at least 12 months of drug exposure data.
Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Biogen Inc. (BIIB) closed the most recent trading day at $280.13, moving -1.18% from the previous trading session.
Biogen (BIIB) Partner Eisai Seeks Nod for Lecanemab in Japan
by Zacks Equity Research
Biogen's (BIIB) partner Eisai files a marketing authorization application for lecanemab for treating early Alzheimer's disease in Japan.
Prothena (PRTA) Stock Gains 88.5% in 6 Months: What Lies Ahead?
by Zacks Equity Research
Prothena (PRTA) surges 88% in the last six months as investors are optimistic on its promising Alzheimer???s Disease pipeline.
Biogen Inc. (BIIB) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Biogen Inc. (BIIB) closed at $288.08 in the latest trading session, marking a +1.07% move from the prior day.
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
by Zacks Equity Research
Sector ETF report for XBI